MK-0457, also known as Tozasertib or VX-680 is a small molecule inhibitor of several tyrosine kinases and serine/threonine kinases, mainly targeting Aurora A kinase and Aurora B kinase. The research on MK-0457 states that it provides an approach targeted at suppressing cancerous growth and has potential in treating several other disorders. This article will provide a comprehensive overview of MK-0457, including its chemical structure, potential benefits, side effects, dosage information, and more.
Chemical name: N-(4-(4-(amino)-6-(1-(2-hydroxyethyl)-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-2-ylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3,4-difluorobenzamide
Molecular formula: C30H28F2N8O3S
Formula weight: 628.66
CAS No: 639089-54-6
Top Ten Keywords from Google and Synonyms:
Synonyms:
MK-0457 is also known as Tozasertib or VX-680.
Health Benefits of MK-0457:
MK-0457 has shown potential as a cancer treatment drug. The selectivity of this small molecule is for the inhibition of Aurora kinases A and B, which are primarily associated with cell division and proliferation. Additionally, MK-0457 has shown anti-tumor activity in preclinical models, leading to its evaluation in clinical trials for the treatment of solid tumors and hematologic malignancies.
Potential Effects of MK-0457:
MK-0457 has been studied for its potential effects on cancer cells. As an Aurora kinase inhibitor, MK-0457 causes defective spindle formation leading to mitotic arrest and subsequent apoptosis. Moreover, it reduces cancer cell proliferation by inhibiting serine-threonine kinases such as AKT and mTOR. The combined effects lead to suppressed cancer cell progression and growth, leading to its consideration as a therapeutic candidate for various types of cancer.
Product Mechanism:
MK-0457 acts as an inhibitor of Aurora kinases A and B that work to promote proper mitotic progression. These kinases are critical to the organization of spindle microtubules, separation of chromosomes, and DNA repair during cell division. By inhibiting Aurora kinases A and B, MK-0457 obstructs the dynamic balance of these events leading to mitotic defects and apoptosis.
Safety:
Early studies indicate that MK-0457 has moderate toxicity. When administered at higher doses, it exhibits side effects such as neutropenia, sepsis, and deranged liver function tests. As a result, cautious monitoring is necessary to avoid severe side effects.
Side Effects:
The most commonly observed side effects of MK-0457 include fatigue, rash, nausea, and diarrhea. Reports also exist of anorexia and weight loss, as well as gastrointestinal bleeding, neutropenia, and QT interval prolongation.
Dosing Information:
The appropriate dosage of MK-0457 varies depending on the individual's specific condition being treated, the degree of cancer progression, and other factors. In clinical trials, MK-0457 has been administered orally, with dosages ranging from 50 to 600 mg per day. It is essential to seek guidance from a medical professional regarding the proper dosage.
Conclusion:
MK-0457 has demonstrated potential as a promising therapeutic candidate for the treatment of various types of cancer. Its primary target, Aurora kinase A and B, are essential for proper mitotic progression, making MK-0457 a potentially useful anticancer drug. However, the safety and efficacy of MK-0457 have yet to be fully determined, and further preclinical and clinical studies are needed before making conclusions regarding it. Still, researchers continue to explore the potential of MK-0457 for cancer treatment and its benefits outweigh the side effects.
